SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?


To: Susan Saline who wrote (20222)7/14/1999 10:38:00 PM
From: DanZ  Respond to of 53068
 
VPHM and GUMM.

I think VPHM is a good short tomorrow, albeit a risky one. The stock is way up on news that their experimental drug, Pleconaril, reduces symptoms of a severe form of the common cold called viral respiratory infection. I think this is a good short because the drug won't be available for a minimum of two years, ViroPharma has insufficient cash to conduct phase III trials, the drug will have limited application even if it makes it into drug stores, the stock has been overly hyped, and it has almost tripled in two days.

GUMM broke resistance at 13 late today on high volume. The stock traded about 100,000 shares in the last 10 minutes as it cleared 13. I think it could run to 15 before it runs into more short term resistance. GumTech's story is similar to Viropharma except GumTech already has Zicam, an OTC cold remedy, in retail stores. Their functional chewing gum business is also picking up steam and should be profitable in Q2 99 or Q3 99. This is not a widely followed company and they are not interested in promoting their stock by issuing premature and frivolous press releases. IMO, the stock will trade significantly higher when the cold season begins in September/October. The company submitted the results of their clinical study for Zicam to the New England of Journal and I believe that it will be published in two or three months. There is also the potential for a short squeeze as I posted last week.

Best of luck to everyone.

Dan



To: Susan Saline who wrote (20222)7/14/1999 11:08:00 PM
From: DanZ  Read Replies (1) | Respond to of 53068
 
NETA and SEG.

I like the chart on these two stocks. I think NETA has a shot at the low 30s and SEG to 32 or 33. I'll be watching these for a Z trade tomorrow. Sue, haven't you traded NETA before? How does it look to you?

Thanks,
Dan